Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)
A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001) Read Moreabout Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)
Phase: III
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301) Read Moreabout Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
Phase: III
Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA)
A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171) Read Moreabout Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA)
Phase: III
Ph3 HER2/neu BC (FLAMINGO-01)
A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01) Read Moreabout Ph3 HER2/neu BC (FLAMINGO-01)
Phase: III
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001) Read Moreabout Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase: III
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH) Read Moreabout Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
Phase: III
Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6)
SERENA-6: A Phase III Double-blind Randomised Study to Assess Switching to AZD9833 (a Next Generation Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor Read Moreabout Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6)
Phase: III
Ph1b-XL092 Immun Onco mST
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002) Read Moreabout Ph1b-XL092 Immun Onco mST
Phase: I
Ph2 RO7198457 CRC ctDNA+ Post Resection
A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01) Read Moreabout Ph2 RO7198457 CRC ctDNA+ Post Resection
Phase: II/III
Ph2 Epidemi Colon Cancer
Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001) Read Moreabout Ph2 Epidemi Colon Cancer
Phase: II/III
Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
Ph3 Selin P53 Endo Carcinoma
A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042) Read Moreabout Ph3 Selin P53 Endo Carcinoma
Phase: III
Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
STAR: Zanu in Acala intolerant B-Cell
A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell
Phase: II
Ph2 Asciminib (ABL001) CP-CML
A Phase II multi-center open-label single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)(CABL001AUS08) Read Moreabout Ph2 Asciminib (ABL001) CP-CML
Phase: II
Ph1b-XL092 Immun Onco mST
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002) Read Moreabout Ph1b-XL092 Immun Onco mST
Phase: I
Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
Ph2 MRTX849 Pembro NSCLC KRAS
A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007) Read Moreabout Ph2 MRTX849 Pembro NSCLC KRAS
Phase: II/III
Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%
A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304) Read Moreabout Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%
Phase: III
Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303) Read Moreabout Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)
Phase: III
An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD
Biomarker status NSCLC
MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361) Read Moreabout Biomarker status NSCLC
Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302) Read Moreabout Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
Phase: I
STAR: Zanu in Acala intolerant B-Cell
A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell
Phase: II
Ph2 Epco r/r B-Cell Lymph out pt
A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting (M23-362) Read Moreabout Ph2 Epco r/r B-Cell Lymph out pt
Phase: II
A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase: II/III
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Phase: III
A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1)
Phase: III
A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS
Phase: I/III
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Patients With Myelofibrosis
Phase: I
Ph2 Dara Lena Dexa (DRd) MM I
A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285) Read Moreabout Ph2 Dara Lena Dexa (DRd) MM I
Phase: II
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
Phase: I/II
Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
Ph1b-XL092 Immun Onco mST
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002) Read Moreabout Ph1b-XL092 Immun Onco mST
Phase: I
Ph2 RO7198457 CRC ctDNA+ Post Resection
A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01) Read Moreabout Ph2 RO7198457 CRC ctDNA+ Post Resection
Phase: II/III
Ph2 Epidemi Colon Cancer
Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001) Read Moreabout Ph2 Epidemi Colon Cancer
Phase: II/III
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
Phase: I/II
Ph1b/2 BEMA FGFR2b ST Basket Trial
A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial
Phase: I/II
STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors
A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001) Read Moreabout STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors
Phase: I/II